Vitiligo

Corrective camouflage in a subject with acral vitiligo 

Patient photographs

Before After

Description of the disease

In subjects receiving oncology immunotherapies, skin manifestations are the most common class of immune-related adverse events (irAEs) and are also the first toxicities to appear after initiation of treatment. In this group, vitiligo was typically reported in patients with metastatic melanoma. This typical effect is often not reported and generally no treatment is given, considering that it is limited to the skin and is often mild in severity. However, the negative impact of vitiligo on quality of life can be substantial, particularly in individuals with darker skin types and when the most exposed areas such as the face or hands are affected.

Dermocosmetic management